Fajac I, Burgel P-R. Cystic fibrosis. Presse Med. 2023;52: 104169. https://doi.org/10.1016/j.lpm.2023.104169.

Article  PubMed  Google Scholar 

Mall MA, Burgel P-R, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024;10:53. https://doi.org/10.1038/s41572-024-00538-6.

Article  PubMed  Google Scholar 

Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195–211. https://doi.org/10.1016/S0140-6736(20)32542-3.

Article  CAS  PubMed  Google Scholar 

Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;10:1662. https://doi.org/10.3389/fphar.2019.01662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65–124. https://doi.org/10.1016/S2213-2600(19)30337-6.

Article  CAS  PubMed  Google Scholar 

Gramegna A, Aliberti S, Calderazzo MA, Casciaro R, Ceruti C, Cimino G, et al. The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: an expert-based Delphi consensus. Respi Med. 2023;220: 107455. https://doi.org/10.1016/j.rmed.2023.107455.

Article  Google Scholar 

McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, et al. Improvement in lung clearance index and chest computed tomography scores with elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis aged 12 years and older—the RECOVER trial. Am J Respir Crit Care Med. 2023;208:917–29. https://doi.org/10.1164/rccm.202308-1317OC.

Article  CAS  PubMed  Google Scholar 

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940–8. https://doi.org/10.1016/S0140-6736(19)32597-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13:29–36. https://doi.org/10.1016/j.jcf.2013.06.008.

Article  CAS  PubMed  Google Scholar 

Burgel P-R, Sermet-Gaudelus I, Durieu I, Kanaan R, Macey J, Grenet D, et al. The French Compassionate Program of elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant. Eur Respir J. 2023. https://doi.org/10.1183/13993003.02437-2022.

Article  PubMed  Google Scholar 

Burgel P-R, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, et al. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. Lancet Resp Med. 2024;12:888–900. https://doi.org/10.1016/S2213-2600(24)00208-X.

Article  CAS  Google Scholar 

Burgel P-R, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, et al. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint. Eur Respir J. 2024;63:2301959. https://doi.org/10.1183/13993003.01959-2023.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Kaftrio ANNEX 1-summary of product characteristics. 2020 p. 1–47. https://www.ema.europa.eu/en/documents/product-information/kaftrio-epar-product-information_en.pdf. Accessed 20 Nov 2024.

U.S. Food and Drug Administration. Multi-discipline review Trikafta. 2019. Report No.: 212273Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidiscplineR.pdf. Accessed 20 Nov 2024.

Burgel P-R, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. Rapid improvement after starting elexacaftor–tezacaftor–ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med. 2021;204:64–73. https://doi.org/10.1164/rccm.202011-4153OC.

Article  CAS  PubMed  Google Scholar 

Barry PJ, Mall MA, Álvarez A, Colombo C, De Winter-de Groot KM, Fajac I, et al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385:815–25. https://doi.org/10.1056/NEJMoa2100665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bryrup T, Faurholt-Jepsen D, Pressler T, Henriksen EH, Leo-Hansen C, Nielsen BU, et al. Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis. APMIS. 2024;132:728–33. https://doi.org/10.1111/apm.13453.

Article  CAS  PubMed  Google Scholar 

Alicandro G, Gramegna A, Bellino F, Sciarrabba SC, Lanfranchi C, Contarini M, et al. Heterogeneity in response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. J Cyst Fibros. 2024. https://doi.org/10.1016/j.jcf.2024.04.013.

Article  PubMed  Google Scholar 

Van Der Meer R, Wilms EB, Heijerman HGM. CFTR modulators: does one dose fit all? J Pers Med. 2021;11:458. https://doi.org/10.3390/jpm11060458.

Article  PubMed  PubMed Central  Google Scholar 

Naehrig S, Shad C, Breuling M, Goetschke M, Habler K, Sieber S, et al. Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis. J Pers Med. 2024;14:1065. https://doi.org/10.3390/jpm14101065.

Article  PubMed  PubMed Central  Google Scholar 

Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, et al. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024;86: 102301. https://doi.org/10.1016/j.pupt.2024.102301.

Article  CAS  PubMed  Google Scholar 

Vonk SEM, Altenburg J, Mathôt RAA, Kemper EM. Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor. J Cyst Fibros. 2024;23:1007–9. https://doi.org/10.1016/j.jcf.2024.03.010.

Article  CAS  PubMed  Google Scholar 

Choong E, Sauty A, Koutsokera A, Blanchon S, André P, Decosterd L. Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now? Pharmaceutics. 2022;14:1674. https://doi.org/10.3390/pharmaceutics14081674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mould D, Upton R. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacom Syst Pharma. 2013;2:1–14. https://doi.org/10.1038/psp.2013.14.

Article  CAS  Google Scholar 

Burgel P-R. Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants. Lancet Respir Med. 2024;12:934–5. https://doi.org/10.1016/S2213-2600(24)00249-2.

Article  CAS  PubMed  Google Scholar 

Zheng Y, Rouillon S, Khemakhem M, Balakirouchenane D, Lui G, Abdalla S, et al. A rapid LC–MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma. J Pharm Biomed Anal. 2024;248: 116322. https://doi.org/10.1016/j.jpba.2024.116322.

Article  CAS  PubMed  Google Scholar 

Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203:1522–32. https://doi.org/10.1164/rccm.202102-0509OC.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsai A, Wu S-P, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor/tezacaftor/ivacaftor. Pulm Ther. 2020;6:275–86. https://doi.org/10.1007/s41030-020-00124-7.

Article  PubMed  PubMed Central  Google Scholar 

Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32. https://doi.org/10.1146/annurev.pharmtox.48.113006.094708. (cited 2025 Mar 17).